Authors

Latest:

Real-world Outcomes with Talquetamab

Panelists discuss how they manage talquetamab-specific toxicities including dysgeusia and nail/skin changes through patient preparation, dietary modifications with umami-rich foods, emollients, and extended dosing intervals.

Ori Barzilai, MD

Latest:

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

Latest:

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Nicholas Coupe, MBBS, PhD

Latest:

Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLC

Nicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.

Will Pizii

Latest:

A Breakthrough for the “Lab Brat”

Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.

Ghayas C. Issa, MD

Latest:

Dr Issa on Testing for NPM1 or KMT2A Alterations in AML

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Amanda Blackmon, DO

Latest:

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.

Bijal Shah, MD, MS

Bijal Shah, MD, MS, is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.

Latest:

Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS

Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.

Martin Hutchings, MD, PhD, Copenhagen University Hospital

Latest:

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

Robert Cameron, MD, PhD

Robert Cameron, MD, PhD, is a Hematology/Oncology fellow at the University of Chicago.

Latest:

Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute

Latest:

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

Georg Lenz, MD

Latest:

Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCL

Georg Lenz, MD, discussed the European approval of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

Iván Márquez Rodas, MD, PhD

Latest:

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Catherine Meador, MD, PhD

Latest:

Insights on Resistance Mechanisms and Sequencing Strategies for DLL3-Targeted and ADC Therapies in ES-SCLC

Panelists discussed advances in overcoming resistance in extensive-stage small cell lung cancer, highlighting promising antibody-drug conjugates and immune-based therapies targeting DLL3 and B7-H3, including bispecific T-cell engagers and CAR T cells, while emphasizing the critical need for biomarkers to guide therapy selection and optimize combinations to improve durability, intracranial activity, and patient outcomes amid the challenges of relapse and immune evasion.

Ellen Ball, ANP-FNP

Latest:

Biomarker Testing Standards-of-Care in Breast and Lung Cancer

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Tracy I. George, MD

Latest:

Dr George on the Limitations of Current Diagnostic Tools in Detecting KIT D816V Mutations in ISM

Tracy I. George, MD, discusses and how ultra-sensitive duplex sequencing may address key limitations of current diagnostic tools for indolent systemic mastocytosis.

Anurag Agrawal, MD

Latest:

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Deborah M. Stephens, DO

Latest:

CAR T-Cell Therapies in CLL

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

Pauline Funchain, MD

Latest:

Dr. Funchain on the Rationale for the SWOG S1404 Trial in Melanoma

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

J. Dominic Femino, MD

J. Dominic Femino, MD, is an associate professor of clinical orthopedic surgery at the Keck School of Medicine of USC and the chief of the USC Musculoskeletal Oncology Center.

Latest:

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions

In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.